HOME >> MEDICINE >> NEWS
Studies suggest investigational agent reduces disease activity in MS

BOSTON A new drug under investigation shows a reduction in disease activity in multiple sclerosis (MS), according to two studies that will be presented at the American Academy of Neurology's 59th Annual Meeting in Boston, April 28 May 5, 2007. The drug reduced disease activity as indicated by MRI scans.

Both of the studies involved people with the relapsing-remitting form of MS, where symptoms flare up and then subside. By 24 weeks, treatment with the drug rituximab reduced the number of areas of brain damage, or lesions, in people with MS and the number of relapses, or times when symptoms flare up, when compared with placebo.

Rituximab is a therapeutic antibody that selectively targets and depletes a subset of immune cells called B-cells by targeting a specific protein on their surface.

"This is the first drug to target B-cells and may represent a potential new treatment strategy for relapsing-remitting MS," said study author Stephen Hauser, MD, of the University of California, San Francisco, and a member of the American Academy of Neurology. "While these are early stage clinical trials, these results are exciting, because the current drugs available for MS are only partially effective in reducing disease activity and preventing exacerbations. New and more effective treatments for MS are sorely needed, especially for people who do not adequately respond to currently available medications. These data are also important because they demonstrate that B-cells, which are the precursors of antibody-producing cells, play an essential role in mediating relapses of MS."

In the first study, a randomized, placebo-controlled trial, 69 people were given two infusions of rituximab two weeks apart and 35 were given a placebo. The participants were followed for six months. Those given rituximab had approximately 90 percent fewer brain lesions than those given placebo. During the six-month period, 58 percent fewer of those taking the d
'"/>

Contact: Angela Babb
ababb@aan.com
651-695-2789
American Academy of Neurology
1-May-2007


Page: 1 2 3

Related medicine news :

1. Studies show antidepressants not linked to birth defects
2. Studies show role of age, gender, race and weight on cancer risk and treatment
3. Studies highlight advances in diagnosis, medical therapy
4. Studies highlight real world use, safety of drug-eluting stents
5. Studies led by Rhode Island Hospital confirm safety and efficacy
6. Studies identify food sources of disease and drug resistance
7. Studies provide new evidence on risks associated with Cox-2 inhibitors and NSAIDs
8. Studies highlight need to monitor heart function in breast cancer patients
9. Studies examine physician disclosure of medical errors
10. Studies indicate medication can be an effective therapy for smoking cessation
11. Studies evaluating health effects of dental amalgam fillings in children confirm safety

Post Your Comments:
(Date:5/23/2015)... (PRWEB) May 23, 2015 Javon ... at the Sports Medicine and Rehabilitation Center, 557 N. ... program, Mondays, June 1-July 20, 5:30-6:30 pm. , The ... coach, and Laurie Finke, RN, BSN, who will offer ... education on nutrition, running mechanics and show selection and ...
(Date:5/22/2015)... The world is at a "hinge ... to create new opportunities for leadership in health ... WesternU's 34th annual Commencement Exercises said Wednesday, May ... former San Francisco mayor and likely 2018 gubernatorial ... ceremony for WesternU's colleges of Allied Health Professions ...
(Date:5/22/2015)... Mountain Point Medical Center, a campus of Jordan Valley ... May 29, 2015 at 11 a.m., followed by a community ... center, set to officially open on June 1, 2015, is ... , “The opening of Mountain Point Medical Center is an ... said Kent Loosle, CEO of Mountain Point Medical Center. “Mountain ...
(Date:5/22/2015)... May 22, 2015 Following yesterday’s announcement ... agreement with US-based health brand Nature’s Way, Marc St-Onge ... Retention of Ascenta Skin is an integral part of ... about this opportunity to further develop Ascenta Skin into ... Ascenta Skin is a breakthrough, anti-aging skincare supplement featuring ...
(Date:5/22/2015)... NY (PRWEB) May 22, 2015 Hands ... that June 17, 2015, the Annual One Day Sale ... Since 2007, Hands On HCMT offers drastically reduced certificates one ... and estheticians have enough sessions, through what used to be ... is wonderful for the community as well. This once a ...
Breaking Medicine News(10 mins):Health News:Newsom to WesternU Grads: The Future is Inside You 2Health News:Newsom to WesternU Grads: The Future is Inside You 3Health News:Mountain Point Medical Center, a Campus of Jordan Valley Medical Center, Hosts Ribbon Cutting Ceremony and Community Celebration on Friday, May 29, 2015 2Health News:Ascenta Skin President Announces Plans to Grow Brand 2Health News:Hands On HealthCare Massage Therapy & Wellness Day Spa Announces Their Eighth Annual One Day Sale on Gift Certificates Will Take Place on June 17, 2015 2Health News:Hands On HealthCare Massage Therapy & Wellness Day Spa Announces Their Eighth Annual One Day Sale on Gift Certificates Will Take Place on June 17, 2015 3
(Date:5/22/2015)... May 22, 2015 The North American ... and is estimated to reach $90.7 million by 2019, at ... Browse through the TOC of North America Dental Lasers Market ... help of various tables and figures. http://www.micromarketmonitor.com/market/north-america-dental-lasers-1771208223.html ... on this report.   Dental lasers are ...
(Date:5/22/2015)... 22, 2015  The U.S. Food and Drug ... the first biosimilar product approved in ... growth in the contract manufacturing organization (CMO) industry, ... is geared to the production of small-molecular drugs ... products. The healthcare market research publisher,s report, ...
(Date:5/22/2015)... 2015  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the ... of the results of the Company,s 72-patient, placebo-controlled ... drops) for the treatment of dry eye patients ... ) model.  The exploratory study was completed in ... disseminated by the Company in a press release, ...
Breaking Medicine Technology:North America Dental Lasers Market is Expected to Reach $90.7 Million by 2019, at a CAGR of 9.2% From 2014 to 2019 2North America Dental Lasers Market is Expected to Reach $90.7 Million by 2019, at a CAGR of 9.2% From 2014 to 2019 3Kalorama: First FDA-Approved Biosimilar Brings Hope for CMO Growth 2Kalorama: First FDA-Approved Biosimilar Brings Hope for CMO Growth 3Kalorama: First FDA-Approved Biosimilar Brings Hope for CMO Growth 4Complete Data from RegeneRx Phase II Dry Eye Trial Published in Current Issue of Clinical Ophthalmology 2Complete Data from RegeneRx Phase II Dry Eye Trial Published in Current Issue of Clinical Ophthalmology 3Complete Data from RegeneRx Phase II Dry Eye Trial Published in Current Issue of Clinical Ophthalmology 4
Cached News: